A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

被引：0
|
作者：
Hong, Hyeyeon [1 ]
Choi, Jonggi [1 ]
机构：
[1] Univ Ulsan, Asan Med Ctr, Ctr Liver, Coll Med,Dept Gastroenterol, 88 Olymp ro 43 gil, Seoul 05505, South Korea
来源：
KOREAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 83卷 / 06期
关键词：
D O I：
10.4166/kjg.2024.048
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：253 / 255
页数：3
相关论文
共 50 条
  • [1] A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
    Harrison, Stephen A.
    Bedossa, Pierre
    Guy, Cynthia D.
    Schattenberg, Joern M.
    Loomba, Rohit
    Taub, Rebecca
    Labriola, Dominic
    Moussa, Sam E.
    Neff, Guy W.
    Rinella, Mary E.
    Anstee, Quentin M.
    Abdelmalek, Manal F.
    Younossi, Zobair
    Baum, Seth J.
    Francque, Sven
    Charlton, Michael R.
    Newsome, Philip N.
    Lanthier, Nicolas
    Schiefke, Ingolf
    Mangia, Alessandra
    Pericas, Juan M.
    Patil, Rashmee
    Sanyal, Arun J.
    Noureddin, Mazen
    Bansal, Meena B.
    Alkhouri, Naim
    Castera, Laurent
    Rudraraju, Madhavi
    Ratziu, Vlad
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (06): : 497 - 509
  • [2] A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis Reply
    Sabet, Amin
    Harrison, Stephen A.
    Taub, Rebecca
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (17): : 1632 - 1633
  • [3] Resmetirom proves positive for NASH with liver fibrosis
    Ray, Katrina
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2024, 21 (04) : 218 - 218
  • [4] Resmetirom proves positive for NASH with liver fibrosis
    Katrina Ray
    Nature Reviews Gastroenterology & Hepatology, 2024, 21 : 218 - 218
  • [5] Reduction in Fibrosis and Steatohepatitis Imaging and Biomarkers in a Phase 3 52 Week Resmetirom NASH Trial
    Harrison, Stephen
    Alkhouri, Naim
    Taub, Rebecca
    Neff, Guy
    Baum, Seth J.
    Younes, Ziad H.
    Bashir, Mustafa
    JOURNAL OF HEPATOLOGY, 2021, 75 : S200 - S200
  • [6] ALGORITHM FOR PREDICTING ADVANCED NASH FIBROSIS ON SCREENING BIOPSY IN RESMETIROM PHASE 3 MAESTRO-NASH CLINICAL TRIAL
    Harrison, Stephen A.
    Taub, Rebecca A.
    Karsdal, Morten Asser
    France, John
    Bashir, Mustafa
    Barbone, Jordan Mark
    Neff, Guy
    Gunn, Nadege T.
    Moussa, Sam
    HEPATOLOGY, 2020, 72 : 1008 - 1009
  • [7] In NASH with liver fibrosis, resmetirom improved NASH resolution and reduced fibrosis at 1 y
    Mironova, Maria
    Sherker, Averell H.
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (06) : JC63 - JC63
  • [8] RESMETIROM EFFECTS ON NASH WITH LIVER FIBROSIS IN PATIENTS WITH NASH GENETIC RISK ALLELES
    Chalasani, Naga
    Labriola, Dominic
    Taub, Rebecca
    Anstee, Quentin
    HEPATOLOGY, 2024, 80 : S1565 - S1566
  • [9] Editorial: Resmetirom - a promising treatment option for NASH and liver fibrosis
    Targher, Giovanni
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (01) : 128 - 129
  • [10] Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
    Stephen A. Harrison
    Rebecca Taub
    Guy W. Neff
    K. Jean Lucas
    Dominic Labriola
    Sam E. Moussa
    Naim Alkhouri
    Mustafa R. Bashir
    Nature Medicine, 2023, 29 : 2919 - 2928
12345